Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Waldenstrom Macroglobulinemia"" wg kryterium: Temat


Tytuł :
Lymphoplasmacytic lymphoma in a patient with Birt-Hogg-Dubé syndrome.
Autorzy :
Kurata K; Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. .
Matsumoto H; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Jimbo N; Department of Diagnostic Pathology, Kobe University Hospital, Kobe, Japan.
Yakushijin K; Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Yamamoto K; Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Ito M; Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Nakamachi Y; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Matsuoka H; Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Saegusa J; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Seyama K; Divisions of Respiratory Medicine, Faculty of Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Itoh T; Department of Diagnostic Pathology, Kobe University Hospital, Kobe, Japan.
Minami H; Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Dec; Vol. 112 (6), pp. 864-870. Date of Electronic Publication: 2020 Aug 12.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Birt-Hogg-Dube Syndrome/*complications
Birt-Hogg-Dube Syndrome/*genetics
Waldenstrom Macroglobulinemia/*etiology
Waldenstrom Macroglobulinemia/*genetics
Antigens, CD20 ; Biomarkers, Tumor ; Exons/genetics ; Female ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Humans ; Middle Aged ; Myeloid Differentiation Factor 88/genetics ; Positron Emission Tomography Computed Tomography ; Proto-Oncogene Proteins/genetics ; Syndecan-1 ; Tumor Suppressor Proteins/genetics ; Waldenstrom Macroglobulinemia/diagnosis ; Waldenstrom Macroglobulinemia/pathology
Czasopismo naukowe
Tytuł :
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies.
Autorzy :
Varettoni M; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Ferrari A; Hematology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Frustaci AM; Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Ferretti VV; Service of Biometry and Clinical Epidemiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Rizzi R; Department of Emergency and Organ Transplantation 'Aldo Moro', University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico, Bari, Italy.
Motta M; Department of Hematology, ASST-Spedali Civili, Brescia, Italy.
Piazza F; Department of Medicine (DIMED), Haematology and Clinical Immunology Section, Padua University School of Medicine, Padua, Italy.
Merli M; Division of Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese, Italy.
Benevolo G; Department of Hematology, Citta' della Salute e della Scienza, Torino, Italy.
Visco C; Medicine, Section of Hematology, University of Verona, Verona, Italy.
Laurenti L; Dipartimento Universitario di Scienze Radiologiche ed Ematologiche, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italy.
Ferrero S; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy/AOU 'Città della Salute e della Scienza di Torino', Torino, Italy.
Gentile M; Division of Hematology, Cosenza, Italy.
Del Fabro V; Division of Hematology, Azienda Policlinico-OVE, University of Catania, Catania, Italy.
Abbadessa A; Istituto Clinico Ruesch, Naples, Italy.
Klersy C; Service of Biometry and Clinical Epidemiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Musto P; Department of Emergency and Organ Transplantation 'Aldo Moro', University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico, Bari, Italy.
Fabbri N; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Deodato M; Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Dogliotti I; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy/AOU 'Città della Salute e della Scienza di Torino', Torino, Italy.
Greco C; Division of Hematology, Vicenza, Italy.
Corbingi A; Dipartimento Universitario di Scienze Radiologiche ed Ematologiche, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italy.
Luminari S; Hematology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy.; Department CHIMOMO, University of Modena and Reggio Emilia, Reggio Emilia, Italy.
Arcaini L; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1473-1478. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Immunotherapy*
Stem Cell Transplantation*
Waldenstrom Macroglobulinemia*/mortality
Waldenstrom Macroglobulinemia*/therapy
Pyrazoles/*administration & dosage
Pyrimidines/*administration & dosage
Adult ; Age Factors ; Autografts ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Risk Factors ; Survival Rate
Czasopismo naukowe
Tytuł :
Detection of Residual Tumor With 68Ga-Pentixafor PET/CT in a Patient With Waldenström Macroglobulinemia and Concurrent John Cunningham Virus-Related Progressive Multifocal Leukoencephalopathy.
Autorzy :
Pan Q; From the Departments of Nuclear Medicine.; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
Luo Y; From the Departments of Nuclear Medicine.; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
Qian M; Neurology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital.
Pokaż więcej
Źródło :
Clinical nuclear medicine [Clin Nucl Med] 2020 Oct; Vol. 45 (10), pp. 792-794.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Coordination Complexes*
Peptides, Cyclic*
Positron Emission Tomography Computed Tomography*
JC Virus/*physiology
Leukoencephalopathy, Progressive Multifocal/*complications
Leukoencephalopathy, Progressive Multifocal/*virology
Waldenstrom Macroglobulinemia/*complications
Waldenstrom Macroglobulinemia/*diagnostic imaging
Aged ; Humans ; Male ; Neoplasm, Residual ; Rituximab/therapeutic use ; Waldenstrom Macroglobulinemia/pathology ; Waldenstrom Macroglobulinemia/therapy
Czasopismo naukowe
Tytuł :
[Watch out for a second train].
Autorzy :
Bravetti C; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Le Garff-Tavernier M; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
De Septenville A; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Maloum K; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Toutée A; Service d'ophtalmologie, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Charlotte F; Service d'anatomopathologie, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Lavaud A; Service d'hématologie clinique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Choquet S; Service d'hématologie clinique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Chapiro É; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Maillon A; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Davi F; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Costopoulos M; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Degaud M; Service d'hématologie biologique, Hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, Paris, France.
Pokaż więcej
Transliterated Title :
Un train peut en cacher un autre.
Źródło :
Annales de biologie clinique [Ann Biol Clin (Paris)] 2020 Oct 01; Vol. 78 (5), pp. 527-536.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Carcinoma, Transitional Cell/*diagnosis
Eye Neoplasms/*secondary
Lymphoma, Large B-Cell, Diffuse/*diagnosis
Lymphoma, Large B-Cell, Diffuse/*pathology
Monoclonal Gammopathy of Undetermined Significance/*diagnosis
Urinary Bladder Neoplasms/*diagnosis
Waldenstrom Macroglobulinemia/*diagnosis
Aged ; Carcinoma, Transitional Cell/blood ; Carcinoma, Transitional Cell/complications ; Diagnosis, Differential ; Eye Neoplasms/blood ; Eye Neoplasms/diagnosis ; Hematologic Tests ; Humans ; Immunoglobulin M/analysis ; Immunoglobulin M/blood ; Immunophenotyping ; Incidental Findings ; Lymphoma, Large B-Cell, Diffuse/blood ; Lymphoma, Large B-Cell, Diffuse/complications ; Male ; Monoclonal Gammopathy of Undetermined Significance/blood ; Monoclonal Gammopathy of Undetermined Significance/complications ; Monoclonal Gammopathy of Undetermined Significance/pathology ; Urinary Bladder Neoplasms/blood ; Urinary Bladder Neoplasms/complications ; Urothelium/pathology ; Vision, Low/diagnosis ; Vision, Low/etiology ; Waldenstrom Macroglobulinemia/blood ; Waldenstrom Macroglobulinemia/complications ; Waldenstrom Macroglobulinemia/pathology
Czasopismo naukowe
Tytuł :
Detection of the MYD88 mutations by cell-free DNA in Waldenström macroglobulinemia.
Autorzy :
Wu YY; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Jia MN; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Cai H; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Qiu Y; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Zhou DB; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Li J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Cao XX; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Aug; Vol. 99 (8), pp. 1763-1769. Date of Electronic Publication: 2020 Jun 23.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Mutation, Missense*
Real-Time Polymerase Chain Reaction*
Cell-Free Nucleic Acids/*genetics
Myeloid Differentiation Factor 88/*genetics
Neoplasm Proteins/*genetics
Receptors, CXCR4/*genetics
Waldenstrom Macroglobulinemia/*genetics
Aged ; Aged, 80 and over ; Amino Acid Substitution ; Cell-Free Nucleic Acids/blood ; Female ; Humans ; Male ; Middle Aged ; Myeloid Differentiation Factor 88/blood ; Neoplasm Proteins/blood ; Receptors, CXCR4/blood ; Sensitivity and Specificity ; Waldenstrom Macroglobulinemia/blood ; Waldenstrom Macroglobulinemia/therapy
Czasopismo naukowe
Tytuł :
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
Autorzy :
Sekiguchi N; Department of Hematology, National Hospital Organization Disaster Medical Center, Tachikawa, Japan.
Rai S; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Munakata W; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Handa H; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Shibayama H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Endo T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Terui Y; Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Iwaki N; Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Fukuhara N; Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tatetsu H; Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Ishikawa T; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Shiibashi R; Department of Clinical Development, Ono Pharmaceutical Co., LTD., Osaka, Japan.
Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Sep; Vol. 111 (9), pp. 3327-3337. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Imidazoles/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Aged ; Aged, 80 and over ; Biomarkers ; Female ; Genotype ; Humans ; Imidazoles/administration & dosage ; Imidazoles/adverse effects ; Male ; Middle Aged ; Mutation ; Myeloid Differentiation Factor 88/genetics ; Myeloid Differentiation Factor 88/metabolism ; Neoplasm Grading ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Receptors, CXCR4/genetics ; Receptors, CXCR4/metabolism ; Treatment Outcome ; Waldenstrom Macroglobulinemia/diagnosis ; Waldenstrom Macroglobulinemia/etiology
Czasopismo naukowe
Tytuł :
Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
Autorzy :
Garcia-Reyero J; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Martinez Magunacelaya N; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Gonzalez de Villambrosia S; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Gomez Mediavilla A; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Urquieta Lam M; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Insunza A; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Tonda R; Centre Nacional d'Anàlisi Genòmica (CNAG-CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Catalunya, Spain.
Beltran S; Centre Nacional d'Anàlisi Genòmica (CNAG-CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Catalunya, Spain.
Gut M; Centre Nacional d'Anàlisi Genòmica (CNAG-CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Catalunya, Spain.
Gonzalez A; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Montes-Moreno S; Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain .
Pokaż więcej
Źródło :
Journal of clinical pathology [J Clin Pathol] 2020 Sep; Vol. 73 (9), pp. 571-577. Date of Electronic Publication: 2020 Jan 24.
Typ publikacji :
Journal Article
MeSH Terms :
Lymphoma/*diagnosis
Monoclonal Gammopathy of Undetermined Significance/*diagnosis
Waldenstrom Macroglobulinemia/*diagnosis
Aged ; Aged, 80 and over ; Alleles ; Biopsy ; Bone Marrow/pathology ; Female ; Humans ; Lymphoma/genetics ; Lymphoma/pathology ; Male ; Middle Aged ; Monoclonal Gammopathy of Undetermined Significance/genetics ; Monoclonal Gammopathy of Undetermined Significance/pathology ; Mutation ; Waldenstrom Macroglobulinemia/genetics ; Waldenstrom Macroglobulinemia/pathology
Czasopismo naukowe
Tytuł :
An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Autorzy :
Lim KJC; Department of Haematology, St Vincent's Hospital , Melbourne, Australia.
Tam CS; Department of Haematology, Peter MacCallum Cancer Centre , Melbourne, Australia.; Department of Medicine, University of Melbourne , Melbourne, Australia.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Sep; Vol. 21 (13), pp. 1555-1564. Date of Electronic Publication: 2020 Jun 30.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Pyrazoles/*therapeutic use
Pyrimidines/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Adult ; Clinical Trials as Topic ; Humans ; Salvage Therapy ; Survival Rate ; Treatment Outcome ; Waldenstrom Macroglobulinemia/genetics ; Waldenstrom Macroglobulinemia/immunology
Czasopismo naukowe
Tytuł :
Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
Autorzy :
Knauf W; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany.
Abenhardt W; Onkologie Gilching, Gilching, Germany.
Slawik HR; Onkologische Schwerpunktpraxis, Augsburg, Germany.
Bückner U; Hämatologisch-onkologische Schwerpunktpraxis, Bochum, Germany.
Otremba B; Onkologische Praxis Oldenburg Delmenhorst, Oldenburg, Germany.
Sauer A; Medizinisches Versorgungszentrum für Blut- und Krebserkrankungen, Potsdam, Germany.
Zahn MO; Medizinisches Versorgungszentrum Onkologische Kooperation, Goslar, Germany.
Wetzel N; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.
Kaiser-Osterhues A; Medical Department, iOMEDICO, Freiburg, Germany.
Houet L; Medical Department, iOMEDICO, Freiburg, Germany.
Marschner N; Praxis für Interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany.
Pokaż więcej
Corporate Authors :
TLN-Group (Tumour Registry Lymphatic Neoplasms)
Źródło :
Hematological oncology [Hematol Oncol] 2020 Aug; Vol. 38 (3), pp. 344-352. Date of Electronic Publication: 2020 May 08.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Waldenstrom Macroglobulinemia/*mortality
Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate ; Waldenstrom Macroglobulinemia/pathology
Czasopismo naukowe
Tytuł :
Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
Autorzy :
Ahn A; Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Park CJ; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. .
Cho YU; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Jang S; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Seo EJ; Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Lee JH; Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Yoon DH; Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Suh C; Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Pokaż więcej
Źródło :
Annals of laboratory medicine [Ann Lab Med] 2020 May; Vol. 40 (3), pp. 193-200.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Marrow/*pathology
Waldenstrom Macroglobulinemia/*diagnosis
Aged ; Aged, 80 and over ; Antigens, CD20/metabolism ; B-Lymphocytes/cytology ; B-Lymphocytes/metabolism ; Bone Marrow/metabolism ; CD40 Ligand/metabolism ; Diagnosis, Differential ; Flow Cytometry/methods ; Humans ; Immunophenotyping ; Kaplan-Meier Estimate ; Mast Cells/cytology ; Mast Cells/metabolism ; Middle Aged ; Paraproteinemias/complications ; Paraproteinemias/diagnosis ; Plasma Cells/cytology ; Plasma Cells/metabolism ; Retrospective Studies ; Waldenstrom Macroglobulinemia/complications ; Waldenstrom Macroglobulinemia/mortality
Czasopismo naukowe
Tytuł :
Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.
Autorzy :
Sakurai M; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. .
Mori T; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Uchiyama H; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Ago H; Department of Hematology and Oncology, Shimane Prefectural Central Hospital, Izumo, Shimane, Japan.
Iwato K; Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Eto T; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Iwasaki H; Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Kawata T; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takamatsu H; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Yamasaki S; Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Takanashi M; Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.; Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Suzuki R; Department of Oncology and Hematology, Shimane University Hospital, Izumo, Shimane, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Jul; Vol. 99 (7), pp. 1635-1642. Date of Electronic Publication: 2020 May 18.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/methods
Hematopoietic Stem Cell Transplantation*/mortality
Waldenstrom Macroglobulinemia/*mortality
Waldenstrom Macroglobulinemia/*therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant/mortality ; Chemotherapy, Adjuvant/statistics & numerical data ; Combined Modality Therapy/mortality ; Combined Modality Therapy/statistics & numerical data ; Female ; Humans ; Japan/epidemiology ; Lymphoma/mortality ; Lymphoma/therapy ; Male ; Middle Aged ; Recurrence ; Registries ; Retrospective Studies ; Rituximab/therapeutic use ; Societies, Medical ; Transplantation, Homologous ; Treatment Outcome ; Waldenstrom Macroglobulinemia/pathology
Czasopismo naukowe
Tytuł :
Occurrence of lymphoplasmacytic lymphoma in a chronic myeloid leukemia patient following long-term treatment with tyrosine kinase inhibitors: A case report.
Autorzy :
Lee CH; Department of Internal Medicine.
Jeon SY; Department of Internal Medicine.
Yhim HY; Department of Internal Medicine.
Jang KY; Department of Pathology, Chonbuk National University Medical School, Jeonju, Republic of Korea.
Kwak JY; Department of Internal Medicine.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 May; Vol. 99 (19), pp. e19962.
Typ publikacji :
Journal Article
MeSH Terms :
Neoplasms, Second Primary*/blood
Neoplasms, Second Primary*/drug therapy
Neoplasms, Second Primary*/etiology
Neoplasms, Second Primary*/pathology
Waldenstrom Macroglobulinemia*/blood
Waldenstrom Macroglobulinemia*/drug therapy
Waldenstrom Macroglobulinemia*/etiology
Waldenstrom Macroglobulinemia*/pathology
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Fusion Proteins, bcr-abl/*antagonists & inhibitors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biopsy/methods ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Humans ; Immunoglobulin M/blood ; Male ; Prednisone/administration & dosage ; Radiography, Abdominal/methods ; Rituximab/administration & dosage ; Tomography, X-Ray Computed/methods ; Treatment Outcome ; Vincristine/administration & dosage
Czasopismo naukowe
Tytuł :
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Autorzy :
Treon SP; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Castillo JJ; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Skarbnik AP; Lymphoproliferative Disorders Program, Novant Health, Charlotte, NC; and.
Soumerai JD; Department of Medicine, Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA.
Ghobrial IM; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Guerrera ML; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Meid K; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
Yang G; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Pokaż więcej
Źródło :
Blood [Blood] 2020 May 21; Vol. 135 (21), pp. 1912-1915.
Typ publikacji :
Journal Article
MeSH Terms :
Betacoronavirus/*isolation & purification
Coronavirus Infections/*drug therapy
Lung Injury/*prevention & control
Pneumonia, Viral/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Pyrazoles/*therapeutic use
Pyrimidines/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Aged ; COVID-19 ; Coronavirus Infections/complications ; Female ; Humans ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/complications ; Protein Kinase Inhibitors/administration & dosage ; Pyrazoles/administration & dosage ; Pyrimidines/administration & dosage ; SARS-CoV-2 ; Waldenstrom Macroglobulinemia/complications
Czasopismo naukowe
Tytuł :
Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.
Autorzy :
Patel N; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH.
Durkin L; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH.
Bodo J; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH.
Hsi ED; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH.
Pokaż więcej
Źródło :
American journal of clinical pathology [Am J Clin Pathol] 2020 Apr 15; Vol. 153 (5), pp. 646-655.
Typ publikacji :
Journal Article
MeSH Terms :
CD5 Antigens/*metabolism
Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis
Lymphoid Enhancer-Binding Factor 1/*metabolism
Lymphoma, B-Cell, Marginal Zone/*diagnosis
Lymphoma, Follicular/*diagnosis
Waldenstrom Macroglobulinemia/*diagnosis
Aged ; Aged, 80 and over ; Biomarkers, Tumor/metabolism ; Female ; Humans ; Immunohistochemistry ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Lymphoma, B-Cell, Marginal Zone/metabolism ; Lymphoma, B-Cell, Marginal Zone/pathology ; Lymphoma, Follicular/metabolism ; Lymphoma, Follicular/pathology ; Male ; Middle Aged ; Waldenstrom Macroglobulinemia/metabolism ; Waldenstrom Macroglobulinemia/pathology
Czasopismo naukowe
Tytuł :
Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia.
Autorzy :
Zanwar S; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Abeykoon JP; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Durot E; Department of Hematology, University Hospital of Reims and UFR Médecine, Reims, France.
King R; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Perez Burbano GE; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Kumar S; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Gertz MA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Quinquenel A; Department of Hematology, University Hospital of Reims and UFR Médecine, Reims, France.
Delmer A; Department of Hematology, University Hospital of Reims and UFR Médecine, Reims, France.
Gonsalves W; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Cornillet-Lefebvre P; Laboratory of Hematology, University Hospital of Reims and UFR Médecine, Reims, France.
He R; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Warsame R; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Buadi FK; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Novak AJ; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Greipp PT; Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota.
Inwards D; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Habermann TM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Micallef I; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Go R; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Muchtar E; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Kourelis T; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Dispenzieri A; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Lacy MQ; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Dingli D; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Nowakowski G; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Thompson CA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Johnston P; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Thanarajasingam G; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Bennani NN; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Witzig TE; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Villasboas J; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Leung N; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Lin Y; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Kyle RA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Rajkumar SV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Ansell SM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Le-Rademacher JG; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Kapoor P; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Mar; Vol. 95 (3), pp. 274-281. Date of Electronic Publication: 2019 Dec 31.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Lymphoma*/genetics
Lymphoma*/mortality
Mutation, Missense*
Waldenstrom Macroglobulinemia*/genetics
Waldenstrom Macroglobulinemia*/mortality
Cell Transformation, Neoplastic/*genetics
Myeloid Differentiation Factor 88/*genetics
Neoplasm Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; Amino Acid Substitution ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Survival Rate ; Time Factors
Czasopismo naukowe
Tytuł :
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
Autorzy :
Owen RG; St James's University Hospital, Leeds, UK. Electronic address: .
McCarthy H; Royal Bournemouth Hospital, Bournemouth, UK.
Rule S; Plymouth University Medical School, Plymouth, UK.
D'Sa S; University College London Hospitals NHS Trust, London, UK.
Thomas SK; University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Tournilhac O; Clermont-Ferrand University Hospital, Clermont-Ferrand, France/Lymphomas Study Association.
Forconi F; University of Southampton Hospital Trust, Southampton, UK.
Kersten MJ; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; on behalf of the Lunenburg Lymphoma Phase I/II Consortium - HOVON/LLPC.
Zinzani PL; Institute of Hematology University of Bologna, Bologna, Italy.
Iyengar S; Royal Marsden Hospital, London, UK.
Kothari J; Churchill Hospital, Oxford, UK.
Minnema MC; University Medical Centre Utrecht Cancer Centre, Utrecht, The Netherlands; on behalf of the Lunenburg Lymphoma Phase I/II Consortium - HOVON/LLPC.
Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Aurran-Schleinitz T; Institut Paoli Calmette, Marseille, France.
Cheson BD; Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Walter H; Ernest and Helen Scott Haematological Research Institute and Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Greenwald D; Cancer Center of Santa Barbara, Santa Barbara, CA, USA.
Chen DY; Acerta Pharma, South San Francisco, CA, USA.
Frigault MM; Acerta Pharma, South San Francisco, CA, USA.
Hamdy A; Acerta Pharma, South San Francisco, CA, USA.
Izumi R; Acerta Pharma, South San Francisco, CA, USA.
Patel P; Acerta Pharma, South San Francisco, CA, USA.
Wei H; Acerta Pharma, South San Francisco, CA, USA.
Lee SK; Acerta Pharma, South San Francisco, CA, USA.
Mittag D; Acerta Pharma, Oss, The Netherlands.
Furman RR; Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Feb; Vol. 7 (2), pp. e112-e121. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Molecular Targeted Therapy*
Antineoplastic Agents/*therapeutic use
Benzamides/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Pyrazines/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Benzamides/adverse effects ; Benzamides/pharmacology ; Female ; Gastrointestinal Diseases/chemically induced ; Humans ; Male ; Middle Aged ; Myeloid Differentiation Factor 88/genetics ; Neoplasm Proteins/antagonists & inhibitors ; Neutropenia/chemically induced ; Pain/chemically induced ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology ; Pyrazines/adverse effects ; Pyrazines/pharmacology ; Quality of Life ; Recurrence ; Respiratory Tract Infections/etiology ; Salvage Therapy ; Treatment Outcome ; Waldenstrom Macroglobulinemia/enzymology ; Waldenstrom Macroglobulinemia/genetics
Czasopismo naukowe
Tytuł :
Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
Autorzy :
Zanwar S; Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Abeykoon JP; Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.; Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Kapoor P; Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. .; Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. .
Pokaż więcej
Źródło :
Current hematologic malignancy reports [Curr Hematol Malig Rep] 2020 Feb; Vol. 15 (1), pp. 31-43.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Molecular Targeted Therapy*/adverse effects
Proteasome Inhibitors/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Signal Transduction/*drug effects
Waldenstrom Macroglobulinemia/*drug therapy
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; Animals ; Genetic Predisposition to Disease ; Humans ; Mutation ; Myeloid Differentiation Factor 88/genetics ; Myeloid Differentiation Factor 88/metabolism ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Proteasome Inhibitors/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Receptors, CXCR4/antagonists & inhibitors ; Receptors, CXCR4/genetics ; Receptors, CXCR4/metabolism ; Waldenstrom Macroglobulinemia/enzymology ; Waldenstrom Macroglobulinemia/genetics
Czasopismo naukowe
Tytuł :
Crystal-storing histiocytosis leading to the identification of IgG-kappa secreting lymphoplasmacytic lymphoma with crystalline nephropathy.
Autorzy :
Reeders J; Department of Anatomical Pathology, John Hunter Hospital, NSW, Australia.
Arnold C; Department of Anatomical Pathology, Tweed Heads Hospital, NSW, Australia.
Chen J; Department of Anatomical Pathology, Royal North Shore Hospital, NSW, Australia.
Kirwan P; Electron Microscopy Unit, Department of Anatomical Pathology, Concord Hospital, NSW, Australia.
Lynnhtun K; Department of Anatomical Pathology, John Hunter Hospital, NSW, Australia. Electronic address: .
Pokaż więcej
Źródło :
Pathology [Pathology] 2020 Feb; Vol. 52 (2), pp. 283-286. Date of Electronic Publication: 2019 Dec 26.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Histiocytosis/*etiology
Histiocytosis/*pathology
Kidney Diseases/*etiology
Waldenstrom Macroglobulinemia/*complications
Waldenstrom Macroglobulinemia/*pathology
Humans ; Immunoglobulin G ; Immunoglobulin kappa-Chains ; Kidney Diseases/pathology ; Male ; Middle Aged ; Waldenstrom Macroglobulinemia/immunology
Raport
Tytuł :
Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia.
Autorzy :
Buske C; Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, 89081 Ulm, Germany. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Feb; Vol. 7 (2), pp. e85-e86. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji :
Letter
MeSH Terms :
Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Humans ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Treatment Outcome ; Waldenstrom Macroglobulinemia/diagnosis ; Waldenstrom Macroglobulinemia/etiology ; Waldenstrom Macroglobulinemia/metabolism
Opinia redakcyjna
Tytuł :
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Autorzy :
Treon SP; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Xu L; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Guerrera ML; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Jimenez C; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Hunter ZR; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Liu X; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Demos M; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Gustine J; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Chan G; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Munshi M; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Tsakmaklis N; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Chen JG; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Kofides A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Sklavenitis-Pistofidis R; Department of Medicine, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Clinical Research Development and Phase I Unit, CREA Laboratory, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy.
Bustoros M; Department of Medicine, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
Keezer A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Meid K; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Patterson CJ; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Sacco A; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Clinical Research Development and Phase I Unit, CREA Laboratory, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy.
Roccaro A; Clinical Research Development and Phase I Unit, CREA Laboratory, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy.
Branagan AR; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA.
Yang G; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Ghobrial IM; Department of Medicine, Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
Castillo JJ; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Apr 10; Vol. 38 (11), pp. 1198-1208. Date of Electronic Publication: 2020 Feb 21.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Mutation*
Myeloid Differentiation Factor 88/*genetics
Receptors, CXCR4/*genetics
Waldenstrom Macroglobulinemia/*genetics
DNA Copy Number Variations ; Genomics ; Humans ; Pathology, Molecular ; Waldenstrom Macroglobulinemia/drug therapy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies